Please assess the completion status of the following clinical trial:

Trial Title: Replacement of Vitamin D in Patients With Active Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (≥16 years on 1st March 2009) Males and Nonpregnant females~* Active Pulmonary Tuberculosis diagnosed by Sputum Smear positivity for Acid fast bacilli (AFB)~* Diagnosis within one week of inclusion into study~* Not already on antituberculous treatment~* Not receiving vitamin D replacement or supplementation~Exclusion Criteria:~* History of having been treated with antimycobacterial therapy for \< 6 months or with \< 4 first-line anti-tuberculous drugs~* Extra- pulmonary TB~* Immune suppressed; with HIV infection, hepatic, renal failure, malignancy, diabetes mellitus~* Sarcoidosis, hyperparathyroidism~* Already on or requiring corticosteroids, immunosuppressive agents, thiazide diuretics~* Breast feeding or pregnant~* Symptomatic cardiac disease~* Seriously ill or moribund patients with advanced respiratory impairment (cor pulmonale, hypercapnia, respiratory acidosis, congestive cardiac failure)~* Allergy/sensitivity to study drugs or their formulations.~* Concomitant use of drugs known to interfere with vitamin D levels; phenytoin, phenobarbital, carbamazepine, theophylline~* Inability or unwillingness of subject or legal guardian/representative to give written informed consent.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cholecalciferol (Vitamin D) (Type: EXPERIMENTAL): Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL
- SALINE, INTRAMUSCULAR INJECTION (Type: PLACEBO_COMPARATOR): NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial

Based on this trial design, predict the completion outcome and termination type (if applicable).